Drug Profile

VRTX 126

Alternative Names: KRAS G12C inhibitor - VRise Therapeutics; VRTX-126

Latest Information Update: 02 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VRise Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action KRAS protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Colorectal cancer; Non-small cell lung cancer

Most Recent Events

26 Oct 2022 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer and Colorectal cancer presented at the 34^th EORTC-NCI-AACR Symposium (ENA-2022)
30 May 2022 VRTX 126 is available for licensing as of 30 May 2022 (https://www.vrisetx.com/our-science.php)
30 May 2022 VRise Therapeutics plans to initiate clinical trial by H2, 2022 (VRise pipeline, May 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com